Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2087990 | 0.87 | HTT (0.65) | HTTMAPTRAB9ANPSR1KDR | |
| SCHEMBL4174847 | 0.86 | MAPT (0.56) | HTTMAPTRAB9ANPSR1KDR | |
| SCHEMBL28236466 | 0.85 | KDR (0.62) | HTTMAPTRAB9ANPSR1KDR | |
| SCHEMBL2086982 | 0.81 | MAPT (0.50) | HTTMAPTRAB9ANPSR1SMN1; SMN2 | |
| SCHEMBL4171211 | 0.81 | HTT (0.52) | HTTMAPTRAB9ANPSR1KDR | |
| SCHEMBL1522733 | 0.80 | HTT (0.60) | HTTMAPTRAB9ANPSR1SMN1; SMN2 | |
| SCHEMBL28137220 | 0.80 | HTT (0.65) | HTTMAPTRAB9ANPSR1SMN1; SMN2 | |
| SCHEMBL2086011 | 0.79 | NPSR1 (0.44) | HTTMAPTRAB9ANPSR1SMN1; SMN2 | |
| SCHEMBL4611494 | 0.79 | HTT (0.64) | HTTMAPTRAB9ANPSR1SMN1; SMN2 | |
| SCHEMBL15636229 | 0.78 | SLC26A6 (0.56) | HTTMAPTRAB9ANPSR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897612-B2 | Substituted 1,8-naphthyridinecarboxamides for use as prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2009-03-26 | — | — | US | disclosed |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082357-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | HTT 1880/4885MAPT 4642/4885RAB9A 4158/4885 |
| US-20070213335-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | HTT 1880/4885MAPT 4642/4885RAB9A 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.